Reduced circulating levels of <scp>TWEAK</scp> are associated with Gestational Diabetes Mellitus

Simón-Muela, Inmaculada; Llauradó, Gemma; Chacón, Matilde R.; Olona, Montserrat; Näf, Silvia; Maymó-Masip, Elsa; Gil, Pilar; López, Miriam de la Flor; Clemente, José Miguel González; Vendrell, Joan; Megía, Ana

doi:10.1111/eci.12375

Cited by 15 publications

(14 citation statements)

References 36 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As circulating sCD163 levels have been shown to correlate with CD163 expression, macrophage content, and insulin sensitivity in adipose tissue, we speculate that early activation of monocytes/macrophages and infiltration in adipose tissue may be an important event in the early development of GDM, at least in a subgroup of women with increased body mass. The association between sCD163 and insulin resistance at 30 to 32 weeks, as also observed in the above GDM studies, may suggest a role for sCD163 and monocyte/macrophage activations in the normal adaption of insulin resistance in later pregnancy. Thus, our findings may reflect that macrophages exert distinct effects depending on the presence of adiposity, hyperglycaemia, and inflammation.…”

Section: Discussionsupporting

confidence: 69%

“…In addition, they detected increased staining of CD163 in placental tissue, presumably from placental macrophages as well as increased secretion from placental explants suggesting the placenta as an alternative source of increased sCD163 in GDM, although this would have less impact in early pregnancy. The non‐significant increase in sCD163 in another study of 66 GDM and 71 control women at 27 weeks of gestation could partly be related to the relative late sampling. Furthermore, at 14 to 16 weeks, high sCD163 was associated with poorer β‐cell function but only in individuals with high BMI as also observed in T2DM .…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Adipokines and macrophage markers during pregnancy—Possible role for sCD163 in prediction and progression of gestational diabetes mellitus

Ueland

Michelsen

Aukrust

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

Aims The risk of gestational diabetes mellitus (GDM) is increased in overweight and obese women potentially involving secreted mediators from adipose tissue. Our main aim was to evaluate if circulating adipokines and monocyte/macrophage markers were dysregulated in GDM and the influence body mass and indices of glucose metabolism had on this association. We further explored if early detection of these markers improved prediction of GDM and if they remained modified during long‐term follow‐up. Materials and methods Population‐based prospective cohort study in 273 pregnant women with markers measured four times during pregnancy and at 5‐year follow‐up. Results sCD163 was higher (25% at 14‐16 weeks, P < 0.001) and adiponectin lower (−17% at 14‐16 weeks, P < 0.01) early in pregnancy and at 5‐year follow‐up in GDM women, independent of BMI, and other GDM risk factors. Leptin, adiponectin, and chemerin were robustly associated with glucose metabolism throughout pregnancy while sCD163 was inversely associated with β‐cell function early in pregnancy in women with increased BMI. Finally, the markers at 14 to 16 weeks displayed modest discriminatory properties with regard to prediction of GDM (AUC < 0.7). Using a combination of fasting glucose and sCD163, 53% of GDM could be identified when 25% of the population scored positive suggesting some merit in a multimarker approach. Conclusions sCD163 and adiponectin were dysregulated in GDM, independent of body mass. None of the adipokines or monocyte/macrophage activation markers displayed clinically useful properties alone for early detection of GDM. Activation of monocytes/macrophages may be an important event in the early development of GDM.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 92%

Adipokines and macrophage markers during pregnancy—Possible role for sCD163 in prediction and progression of gestational diabetes mellitus

Ueland

Michelsen

Aukrust

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…In the literature, there are contradictory findings of the relationship between TWEAK levels and atherosclerosis (27,28). Previous studies showed a negative relationship between serum TWEAK levels and coronary artery disease, cIMT, insulin resistance, gestational diabetes and type II diabetes (29)(30)(31)(32). However, studies cannot explain the reason why atherosclerotic process accelerated when serum TWEAK levels were low (33).…”

Section: Discussionmentioning

confidence: 99%

Soluble Tumor Necrosis Factor (TNF)-Like Weak Inducer of Apoptosis (Tweak) Independently Predicts Subclinical Atherosclerosis in Behcet’s Disease

İçli̇

Cüre

Cüre³

et al. 2018

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Background: Vasculopathy is a major cause of mortality and morbidity in Behcet’s Disease (BD). Subclinical atherosclerosis can even be detected in the early stage of BD. Soluble tumor necrosis factor-like (TNF) weak inducer of apoptosis (TWEAK) is known as a good marker of the inflammation in vascular tree. The aim of this study is to examine the relationship between carotid artery intima-media thickness (cIMT) and serum TWEAK levels in patients with BD. Materials and Methods: In line with International BD Study Group criteria, 48 BD, and 30 controls were included in our study. Disease activity was evaluated according to BD current activity form (BDCAF). C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lipid parameters, serum TWEAK levels, and cIMT were measured. Results: Disease activity score of BD patients was found as 2 (range 0–7). cIMT, serum TWEAK, CRP and ESR levels of BD patients were significantly higher comparing to cIMT (0.62 ± 0.13 mm vs. 0.43 ± 0.09 mm, p < 0.001), serum TWEAK (667.5 ± 130.6 vs. 603.4 ± 89.6 pg/ml, p = 0.015), CRP (3.9 ± 4.3 vs. 1.4 ± 1.0 mg/dl, p < 0.001) and ESR (10.2 ± 10.0 vs. 5.6 ± 3.7 mm/h, p = 0.005) levels of the control group. There was a positive correlation between serum TWEAK level and disease activity (r = 0.251, p = 0.030) and cIMT (r = 0.463, p < 0.001). Our study also revealed an independent correlation between cIMT and serum TWEAK levels (beta = 0.354, p < 0.001). Conclusion: Increased serum TWEAK levels can play a part in the development of atherosclerotic heart disease in BD. Due to their liability to atherosclerosis, patients with BD must followed closely.

show abstract

“…There are not many studies on the relationship between pregnancy related diseases and sTWEAK in the literature. Recently Simón-Muela et al showed decreased sTWEAK levels in patients with gestational diabetes compared to control subjects [ 27 ]. The authors related their finding to decreased insulin sensitivity, consistent with the previous report of Kralisch et al [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Soluble TNF-Like Weak Inducer of Apoptosis as a New Marker in Preeclampsia: A Pilot Clinical Study

et al. 2016

View full text Add to dashboard Cite

Introduction. All findings of preeclampsia appear as the clinical consequences of diffuse endothelial dysfunction. Soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) was recently introduced as a TNF related cytokine in various inflammatory and noninflammatory disorders. sTWEAK was found to be related to endothelial dysfunction in patients with chronic kidney disease. In our study we aimed to compare sTWEAK levels in women with preeclampsia to corresponding levels in a healthy pregnant control group. Materials and Methods. The study was undertaken with 33 patients with preeclampsia and 33 normal pregnant women. The concentration of sTWEAK in serum was calculated with an enzyme linked immunosorbent assay (ELISA) kit. Results. Serum creatinine, uric acid, LDH levels, and uPCR were significantly higher in the patient group compared to the control group. sTWEAK levels were significantly lower in preeclamptic patients (332 ± 144 pg/mL) than in control subjects (412 ± 166 pg/mL) (p = 0.04). Discussion. Our study demonstrates that sTWEAK is decreased in patients with preeclampsia compared to healthy pregnant women. There is a need for further studies to identify the role of sTWEAK in the pathogenesis of preeclampsia and to determine whether it can be regarded as a predictor of the development of preeclampsia.

show abstract

Reduced circulating levels of TWEAK are associated with Gestational Diabetes Mellitus

Cited by 15 publications

References 36 publications

Adipokines and macrophage markers during pregnancy—Possible role for sCD163 in prediction and progression of gestational diabetes mellitus

Adipokines and macrophage markers during pregnancy—Possible role for sCD163 in prediction and progression of gestational diabetes mellitus

Soluble Tumor Necrosis Factor (TNF)-Like Weak Inducer of Apoptosis (Tweak) Independently Predicts Subclinical Atherosclerosis in Behcet’s Disease

Soluble TNF-Like Weak Inducer of Apoptosis as a New Marker in Preeclampsia: A Pilot Clinical Study

Contact Info

Product

Resources

About